NCT07828327尚未招募不适用
Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience
Qianfoshan Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2026年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of steroid requiring exacerbations
研究概览
简要总结
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
详细描述
Subjects who have been identified to have severe eosinophilic asthma with ABPA will be consented and enrolled in the study to receive Depemokimab injections (100 mg subcutaneous) administered every 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA:Predisposing condition: Bronchial asthma Obligatory criteria (both should be present)Type I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use. Elevated total IgE levels (>1,000IU/mL)* Other criteria (at least two of three)Presence of precipitating or IgG antibodies against Af in serum Radiographic pulmonary opacities consistent with ABPA Total eosinophil count >500 cells/uL in steroid naïve patients (may be historical)(if the patient meets all other criteria, an IgE value <1,000 IU/mL may be acceptable) Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1Other acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and/or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control Documented current treatment with high daily doses of ICS ( >500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1For ICS/LABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study. History of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit
- •For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days. Weight > 40kg
排除标准
- •Clinically important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (i.e., chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoidosis, and pulmonary fibrosis).History of anaphylaxis to any biologic therapy.Known history of allergy or hypersensitivity reaction to Depemokimab or any of its components.Currently pregnant, breastfeeding, or lactating women.Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.
研究组 & 干预措施
Treatment
Experimental
Depemokimab treatment will be given by injections administered every 6 months.
干预措施: Depemokimab (Drug)
结局指标
主要结局
Number of steroid requiring exacerbations
时间窗: 26 weeks
Number of asthma exacerbations requiring the initiation of (or temporary increase in) systemic corticosteroids in severe eosinophilic asthma complicated by ABPA
次要结局
- Patient-Reported Quality of Life as assessed by Saint George Respiratory Questionnaire(26 weeks)
- Asthma Control as assessed by Asthma Control Questionnaire 6(26 weeks)
- Lung Function (FEV1)(26 weeks)
研究者
Qian Qi
Prof.
Qianfoshan Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary AspergillosisAllergic Bronchopulmonary AspergillosisSevere AsthmaABPANCT07757841Qianfoshan Hospital10
招募中
3 期
A Study of Depemokimab in Participants of 6 to 11 Years of AgeAsthmaNCT07671001GlaxoSmithKline34
招募中
不适用
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary AspergillosisAllergic Bronchopulmonary AspergillosisSevere AsthmaABPANCT07530770Qianfoshan Hospital20
招募中
4 期
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Nasal PolypsNCT07701967GlaxoSmithKline28
招募中
不适用
Dupilumab Therapy for EGIDsNCT07257835Children's Hospital of Fudan University20